What it does not do
It is not typically used alone; combination figures are trial-stage, not promises.
What we don't know
Standalone efficacy and long-term safety are less characterized than the combination; the program is ongoing.
Every molecule in this reference has a gap. Here they are, named, by molecule. This is the part the marketing skips — including the ones we sell. Even the best-evidenced compounds here carry open questions, and a gaps page that covered only the things we don't stock would be an availability argument wearing a lab coat.
The presence of research gaps does not mean a molecule is ineffective or unsafe. It means the evidence base is incomplete.
The claims a molecule cannot carry. Written and reviewed as part of the monograph, not generated here.
The open questions in the human evidence. Medical-review owned, and it never gets softened to make a molecule look better.
Nobody has written it yet, and we print the blank rather than invent a sentence. Right now that is 1 of 54 on the first field and 0 on the second.
No availability and no regulatory status appear on this page. Whether you can get something and what the rule says about it are two other questions, answered on the FDA Tracker and on each molecule's own page. Evidence gaps do not move when either of those changes.
Your gut releases hormones after a meal that tell the brain you are full and the pancreas to release insulin. These molecules copy those signals, so appetite falls and blood sugar steadies — which is why they are studied for weight and for diabetes at the same time.
It is not typically used alone; combination figures are trial-stage, not promises.
Standalone efficacy and long-term safety are less characterized than the combination; the program is ongoing.
It is not a peptide, not approved, and not available; we tag it adjacent and capture the query.
Long-term efficacy versus injectable agonists and full safety are still being established.
It is not a guaranteed result; trial figures are not a promise and grey-market product is unverified and unsafe.
Long-term safety and durability are not yet established; the trial program is ongoing and figures may change at peer review and approval.
It is not a cosmetic shortcut and not risk-free; compounded forms are not FDA-approved, and we make no guaranteed-loss claims.
Long-term outcomes of compounded (vs. branded) formulations are less characterized; durability after stopping depends heavily on the habits built alongside it.
It is not approved, not available, and not a liver treatment you can obtain; the MASH data is trial-stage.
Long-term outcomes and the MASH benefit are still being established in Phase-3.
It is not a guaranteed result and not a substitute for the habits that keep the loss; compounded forms are not FDA-approved.
Head-to-head long-term outcome data is still maturing; compounded-formulation specifics differ from the studied branded product.
It is not approved, not available, and the oral-vs-injectable comparison is not yet settled in trials.
Oral bioavailability, durability, and long-term safety are still being established.
Rather than injecting growth hormone, these prompt the pituitary to release more of your own, either by mimicking the releasing hormone or by acting on the ghrelin receptor. The distinction matters: the ceiling is your own physiology, which is a different risk profile from replacement.
It cannot be legally compounded in the US, and Peptós.LIFE does not offer it, it is education only.
Long-term safety of the long-acting (DAC) form is poorly characterized in humans.
It is not approved or available, and remains a restricted research compound.
Long-term endocrine effects are poorly characterized.
It is not approved or available, and the appetite effect limits its appeal.
Long-term endocrine and metabolic effects are poorly characterized.
It is not approved or available, and tolerance plus prolactin effects limit its usefulness.
Long-term endocrine effects and the desensitization curve are poorly characterized.
It is non-compoundable in the US and is not offered by Peptós.LIFE, education only.
Human outcome data is limited; long-term effects are uncharacterized.
It is not a peptide, not FDA-approved, and not offered here.
Effects on long-term glucose metabolism and cardiac parameters need more data.
It is not anabolic steroid therapy and is not a guaranteed performance enhancer.
Long-term outcome data is limited; effects vary with age and baseline.
Compounded versions are not FDA-approved, and it is not a general weight-loss drug.
Long-term use beyond studied indications is less characterized.
These act on the local signalling that surrounds an injury — blood-vessel formation, cell migration, the scaffolding cells build as they rebuild tissue. Almost all of the evidence is in animals and in cell culture, which is why the enthusiasm runs well ahead of the human data.
It is not a proven cure for any injury.
Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.
Topical cosmetic use is a separate thing from any injectable claim, we never conflate the two.
Topical absorption and effect sizes vary by formulation; injectable use is not what this entry covers.
It is not a treatment for any diagnosed gut condition.
Human evidence is sparse; effect on specific conditions is unproven.
The marketed fragment is not trial-grade thymosin beta-4.
Human evidence is minimal and animal-dominant; the marketed fragment differs from studied Tβ4, and antibody responses have been raised.
Mitochondria generate the energy every cell runs on, and they degrade with age and metabolic stress. These molecules are encoded by or target mitochondrial machinery, aiming at how efficiently cells make energy rather than at any single organ or symptom.
It is not a proven therapy, has no approved use.
Human evidence is minimal; therapeutic effects and safety are unestablished.
It is not a proven metabolic treatment.
Human data is preliminary; metabolic effects are not established.
It is not approved for aging, energy, or longevity, and the two-signal rule holds: a real approval for one disease is not a green light for off-label use.
Longevity and general-energy benefits in healthy adults are not established; the approval is narrow (Barth syndrome).
These cross into the central nervous system and act on neurotransmitter and neuropeptide signalling — arousal, mood, focus, sleep. Central action is also why their effects are hard to measure objectively, and why the trial evidence here is thinner than the anecdote.
It is not injectable Botox and not a wrinkle cure; topical effect sizes are modest.
Topical penetration and real-world effect size vary by formulation; it is not a substitute for procedures.
It is not US-approved or available here, and trial quality across the literature is mixed.
Trial quality is heterogeneous; US regulatory path and standardized benefit are unsettled.
It is not a treatment for cognitive decline, dementia, or any diagnosed condition, it has no established human safety record, and it is not something we sell.
Almost everything that matters: no published controlled human efficacy or safety trials, no characterized human dosing, no long-term data, and open questions about growth-factor signaling.
It has no human data, is not approved, and is not a treatment for depression or any mood condition.
No human safety or efficacy data; durability of the antidepressant effect is unknown.
It is not approved for men or for postmenopausal women (those uses are off-label), it is not a blood-flow 'ED pill,' and it is not something we offer. Branded Vyleesi and compounded bremelanotide are different regulatory things.
Formal efficacy and approval in men aren't established; long-horizon repeated-use effects aren't well characterized. Response and tolerability vary, with nausea and transient blood-pressure changes reported.
It is not an anxiety medication and is not a substitute for mental-health care.
Controlled human evidence is limited; durability of effect is unclear.
It is not a treatment for any cognitive or psychiatric condition, and we don't offer it today.
Western trial evidence is minimal; long-term effects are uncharacterized.
Several are fragments of molecules the immune system already uses to coordinate itself, from thymic hormones to antimicrobial peptides. They modulate rather than boost — the distinction is real, because an immune system pushed in the wrong direction is a risk, not a benefit.
It is not approved or available, and the trial evidence is early.
Efficacy and long-term safety are not established beyond early trials.
It is not approved or available, and its pro-inflammatory potential is a real caution.
The line between immune support and harmful inflammation is poorly characterized; no human dosing.
It is not independently validated.
Independent replication is limited; outcomes unconfirmed.
No entry written yet. It is on the content queue, and we would rather show you the hole than fill it with something nobody reviewed.
US regulatory path is unsettled; optimal use outside studied indications is unclear.
These are short peptides from a Soviet-era research programme, proposed to act directly on gene expression in specific tissues. The claim is far-reaching and the independent Western replication is largely absent, so we carry them as a documented tradition rather than an established mechanism.
It is not proven to extend how long you live.
Most data is older and methodologically limited; claims outrun the evidence.
It is not independently validated.
Independent Western replication is scarce; mechanism and outcomes are unconfirmed.
It is not independently validated.
Independent replication is minimal; outcomes unconfirmed.
These sit upstream of the sex hormones, signalling the brain and pituitary to drive the cascade that ends in testosterone or oestrogen. Because they act at the top of a feedback loop, small changes propagate — which is what makes them interesting and what makes them clinician territory.
It is not a peptide and not a substitute for evaluation of the cause of low testosterone.
Long-term outcome data beyond testosterone levels is still maturing.
Compounded forms are not FDA-approved, and it is not a standalone testosterone therapy.
Optimal protocols alongside modern TRT are still being refined.
It is not a proven libido treatment, and it is not offered here.
Optimal dosing and durability of effects on desire are not established.
The off-label intimacy use is not strongly evidenced, and compounded forms are not FDA-approved.
Controlled evidence for off-label intimacy/arousal use is limited; optimal use is not established.
It is not a safe or proven 'hormone restart,' and that off-label biohacker use is inappropriate and not something we offer.
The off-label 'restart' protocol has no controlled evidence and a real risk profile.
A genuinely mixed group whose only shared property is the outcome people hope for: less fat, better sleep, fewer worn-out cells. Grouping by hoped-for result rather than by mechanism is honest here, because these molecules do not share one.
It is not a peptide, not proven in humans, and not a weight-loss treatment.
No credible controlled human evidence of meaningful fat loss; safety uncharacterized.
It is not proven or safe in humans, animal studies showed kidney toxicity.
No credible human safety or efficacy data; renal toxicity is the headline risk.
It did not show meaningful weight loss in controlled human trials, and it is not offered here.
No credible evidence of clinically meaningful fat loss in humans.
It is not a proven sleep medication.
Modern controlled human evidence is scarce; effect on sleep architecture is unconfirmed.
It is not approved or safe, removing the growth brake carries real cardiac and tissue risk.
Long-term cardiac, tendon, and tumor risks of myostatin inhibition are uncharacterized in humans.
It has no human data; the mechanism is powerful and unproven in people.
No human safety or efficacy data; off-target apoptosis risk is uncharacterized.
It is not approved, not safe to obtain, and not appropriate for anyone, its growth signaling is the risk.
Long-term cancer-risk and metabolic effects of sustained IGF signaling are the central uncharacterized concerns.
It is not characterized for human safety.
Human evidence is minimal; growth-signaling safety is uncharacterized.
It is not US-approved, not a peptide, and not safe to obtain off-market given cardiovascular and psychiatric risk.
Long-term cardiovascular and neuropsychiatric safety are the unresolved questions that gate approval.
Rapamycin, metformin, NAD+ and others are small molecules or cofactors, not peptides at all. They appear in every peptide discussion because they target the same goals, and we label them plainly rather than let the category blur.
Evidence is limited to small studies, it is not a peptide, and it is not offered on this surface.
Large randomized trials are lacking; effect sizes vary by condition.
Longevity benefit in non-diabetics is not yet proven, and it is not a peptide.
Whether it extends healthspan in metabolically healthy people is the open question TAME aims to answer.
It is not proven to extend how long you live, and we don't frame it that way.
Longevity evidence in humans is still early; benefits beyond energy/support are not established.
Human lifespan benefit is not proven, and it is not a peptide.
Optimal dose/interval for longevity in humans, and long-term immune effects, are unresolved.
Most of this category sells certainty it does not have. We would rather be the site you can check. If a gap here closes — a trial reads out, a question gets answered — the monograph changes and this page changes with it, because both read the same record. Nothing on this page is written twice.
Related: the full Knowledge Base · what the FDA actually says · how we grade evidence